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Abstract
During early development, modulations in the expression of Nodal, a TGFb family member, determine the specification of
embryonic and extra-embryonic cell identities. Nodal has been extensively studied in the mouse, but aspects of its early
expression remain unaccounted for. We identified a conserved hotspot for the binding of pluripotency factors at the Nodal
locus and called this sequence ‘‘highly bound element’’ (HBE). Luciferase-based assays, the analysis of fluorescent HBE
reporter transgenes, and a conditional mutation of HBE allowed us to establish that HBE behaves as an enhancer, is
activated ahead of other Nodal enhancers in the epiblast, and is essential to Nodal expression in embryonic stem cells (ESCs)
and in the mouse embryo. We also showed that HBE enhancer activity is critically dependent on its interaction with the
pluripotency factor Oct4 and on Activin/Nodal signaling. Use of an in vitro model of epiblast maturation, relying on the
differentiation of ESCs into epiblast stem cells (EpiSCs), revealed that this process entails a shift in the regulation of Nodal
expression from an HBE-driven phase to an ASE-driven phase, ASE being another autoregulatory Nodal enhancer. Deletion
of HBE in ESCs or in EpiSCs allowed us to show that HBE, although not necessary for Nodal expression in EpiSCs, is required
in differentiating ESCs to activate the differentiation-promoting ASE and therefore controls this regulatory shift. Our findings
clarify how early Nodal expression is regulated and suggest how this regulation can promote the specification of extra-
embryonic precusors without inducing premature differentiation of epiblast cells. More generally, they open new
perspectives on how pluripotency factors achieve their function.
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Introduction
The gene Nodal encodes a TGFb family member signaling via
the Smad2/3-dependent Activin/Nodal pathway. Nodal is a key
factor during early development, required for the specification of
cell identities in embryonic and extra-embryonic lineages [1,2]. Its
re-expression in the adult has been associated with tumor
progression and its signaling pathway is essential to the mainte-
nance of human embryonic stem cells (ESCs) [3–5]. There is
therefore a broad interest in understanding how its expression is
initiated and regulated.
In the mouse, Nodal expression starts in the inner cell mass
(ICM) of the E3.5 blastocyst [6,7]. At E4.0, shortly before
implantation, Nodal is detected in the two tissues that derive from
the ICM: the epiblast, which will give rise to all fetal lineages, and
the primitive endoderm (PrE), an extra-embryonic layer [6]. Nodal
expression remains detectable in their postimplantation derivatives
up to gastrulation stages but exhibits complex dynamics,
foreshadowing the establishment of the anterior–posterior axis
and the formation of the primitive streak [1]. Its re-expression in
the node at E7.5 and in left lateral plate mesoderm at E8.0
contributes to the establishment of left–right asymmetry [1].
Nodal expression starts at E3.5, but the earliest molecular defects
characterized in Nodal2/2 embryos so far were detected after
implantation. The epiblast of Nodal2/2 embryos differentiates
prematurely and their visceral endoderm, a derivative of the PrE,
is not properly regionalized [8–10]. Pluripotent cell lines offer
convenient in vitro models to study the role of Nodal and Activin/
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Nodal signaling during epiblast development. ESCs are derived
from the nascent preimplantation epiblast [11]. They express Nodal
and have an active Activin/Nodal signaling pathway, but this is
not essential to their maintenance [3,12]. In contrast, epiblast stem
cells (EpiSCs) are derived from the postimplantation epiblast, and
their capacity to self-renew depends critically on Activin/Nodal
signaling [13,14]. When exposed to Activin and FGF, ESCs can be
converted into EpiSCs, a differentiation process dependent on
Activin/Nodal signaling and described as a transition from a
ground state of pluripotency to a primed state of pluripotency
[11,15]. This protocol is now commonly used to mimic events
surrounding the maturation of the preimplantation epiblast into
postimplantation epiblast.
Several studies showed that in ESCs Nodal expression is
dependent on pluripotency factors or on Activin/Nodal signaling
itself [16–19]. Four Nodal cis-regulatory elements are already
known. None is controlled by pluripotency factors, and only one,
ASE, is both dependent on Activin/Nodal signaling and known to
be active before implantation [6,20,21]. ASE contains two
functional FoxH1-Smad2,3 binding motifs and acts as an
autoregulatory element allowing Nodal to amplify its own
expression, notably in the postimplantation epiblast [20,21]. The
deletion of ASE results in a phenotype far less severe than that of
Nodal2/2 embryos and characterized by later patterning defects
[20], indicating that it is not required to initiate Nodal expression.
Our previous analysis of the expression profiles of fluorescent
reporter transgenes for ASE showed that, although they could
recapitulate some aspects of Nodal expression at preimplantation
stages, they could not account for the timing of its onset in the
ICM and its presence in nascent preimplantation epiblast cells [6].
This strongly suggested that these particular aspects of Nodal
expression are dependent on cis-regulatory sequences other than
ASE.
We sought to uncover how Nodal expression is initiated. We
identified a novel Nodal enhancer, which we call HBE, that
matches the expected profile. HBE is activated ahead of other
Nodal enhancers in the ICM and in the preimplantation epiblast,
and it is the predominant Nodal enhancer in ESCs. Furthermore,
HBE is a hotspot for the binding of pluripotency factors and
mediates the influence of Oct4, Klf4, and Activin/Nodal signaling
on the expression of Nodal. The deletion of HBE by homologous
recombination eliminates expression of the mutated allele in ESCs
and in the early embryo. Strikingly, it also impairs its expression
when ESCs are induced to differentiate, revealing an early
requirement for HBE to trigger the activation of at least one other
enhancer, the ASE, which drives Nodal expression in more
differentiated cell types. We find also that the deletion of HBE
in ESCs results in a region close to ASE accumulating the
repressive histone mark H3K27me3, implying that it is via its
implication in the recruitment of chromatin modifiers that HBE
controls ASE. Our findings shed light on how enhancers regulated
by the molecular machinery of pluripotency control gene
expression and drive development forward.
Results
Identification of HBE, a Novel Nodal Enhancer Active in
Pluripotent Stem Cells
One study identified Nodal as a tentative direct target of the
pluripotency factors Oct4, Sox2, and Nanog in ESCs [19]. It
showed that the expression of Nodal declined when the gene
encoding Oct4 was knocked down, whereas it was upregulated
when Nanog or Sox2 were supressed. We therefore searched
relevant ChIP data, which revealed the existence of a hotspot for
the binding of pluripotency factors, including Oct4, Nanog, Sox2,
and Klf4, in a 2 kb region lying 1 kb upstream of the Nodal
transcription start site (TSS) (Figure 1A) [22–26]. We called this
region HBE, for highly bound element. This noncoding sequence
is conserved in eutherian mammals, an indication that it may be
involved in gene regulation (Figure 1A). In ESCs, this sequence
scores positive for four criteria now used to identify active
enhancers: low levels of the repressive histone mark H3K27me3,
low levels of the active but promoter-associated histone mark
H3K4me3, high levels of the active histone marks H3K4me1 and
H3K27ac, and a binding peak of the acetyltransferase and
transcriptional coactivator p300 [27–31] (Figure S1). In contrast,
none of the known Nodal enhancers, PEE, NDE, AIE/LSE, or
ASE [32–35], appeared to bear the hallmark of an active enhancer
in ESCs (Figure S1). The ASE, however, although not bearing the
active enhancer mark H3K4me1, presents marks suggestive of
possible transcriptional activity: a binding peak for p300, high level
of H3K27ac, and a peak of the active promoter-specific
H3K4me3.
A luciferase-based assay was used to test HBE’s capacity as an
enhancer in ESCs and to compare it to that of ASE and PEE, the
only Nodal enhancers known to be active at peri-implantation
stages [6,36]. This assay was done both with the minimal
promoter E1b [36] and with the 940-bp-long stretch of sequence,
termed NIS, for Nodal intervening sequence, which separates HBE
from the ORF of the gene and contains the endogenous Nodal
promoter. In both cases, HBE came out as the strongest enhancer
(Figure 1B), whereas PEE and ASE showed minimal activity and
NDE and AIE/LSE showed no activity whatsoever. We
performed the same assay in EpiSCs. This time, although HBE
still showed enhancer activity, the activity of ASE was higher while
that of PEE, NDE, and AIE/LSE was unchanged (Figure 1C).
The higher activity of ASE is consistent with it being dependent on
Activin/Nodal signaling [6,20,34] and the presence of Activin in
EpiSC culture medium. These results indicate that HBE is the
predominant Nodal enhancer in ESCs and that it is still active in
EpiSCs.
An HBE Reporter Transgene Is Activated in
Preimplantation Epiblast
To find out when and where HBE is active during embryonic
development, we generated transgenic lines where the expression
of a nuclear version of Venus-YFP is placed under the control of
Author Summary
In the early mouse embryo, Nodal, a member of the
TGFbeta superfamily of signalling proteins, promotes the
differentiation of extra-embryonic tissues, as well as tissues
within the developing embryo itself. Characterising the
regulation of Nodal gene expression is essential to
understand how Nodal signals in diverse tissue types
and at different stages of embryonic development. Four
distinct enhancer sequences have been shown to regulate
Nodal expression, although none could account for it in
the preimplantation epiblast or in embryonic stem cells.
We identified a novel enhancer, HBE, responsible for the
earliest aspects of Nodal expression. We show that
activation of HBE depends on its interaction with a well-
known pluripotency factor called Oct4. HBE itself also
controls the activation of at least one other Nodal
enhancer. Our findings clarify how early Nodal expression
is regulated and reveal how pluripotency factors may
control the onset of differentiation in embryonic tissues.
Control of Nodal Enhancers’ Sequential Activation
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HBE-NIS—that is, the 3 kb of genomic sequence directly
upstream of the Nodal ORF. The two independent HBE-YFP
mouse lines we obtained both showed the same reporter
expression profile, thus precluding the influence of position and
confirming its specificity (Figure 2). The fluorescence was first
detected at E3.5 in one or two cells of the ICM (n=12/15
embryos analyzed; Figure 2A–A0). By E4.5, more ICM cells were
positive and the signal was stronger (Figure 2B–C0, 2E–E0). These
cells all co-expressed the pluripotency factor Oct4 (Figure 2B–B0).
Counts performed on E4.5 embryos stained for the PrE marker
Gata-4 found that 93% of epiblast cells were YFP-positive. Most
YFP-positive cells (98%) were also found to co-express the
pluripotency factor Nanog (Figure 2C–C0). This is in marked
contrast to the ASE-YFP transgene, which showed an expression
profile broadly complementary to that of Nanog in the epiblast
around the time of implantation [6], and suggests that HBE-YFP is
expressed in epiblast cells earlier than ASE-YFP. However, at
these early stages HBE-YFP expression is not restricted to the
embryonic lineage. Co-expression with Gata-4 was detected in a
subset of PrE cells in some embryos at E3.75 and E4.5 (n=3/13
and n=5/11, respectively; Figure 2D–D0, E–E0). There was no
expression in extra-embryonic endoderm after this (unpublished
data and Figure 2F–F0). After implantation, at E5.5, HBE-YFP
was expressed in all epiblast cells, albeit with varying levels of
intensity (n=15/16; Figure 2F–F0). By E6.5, the expression of the
transgene in the epiblast was clearly heterogeneous (n=13/13;
Figure 2G–G0), suggesting it was progressively downregulated in
some cells whereas it was maintained in others. Between E6.5 and
E7.5, HBE-YFP–positive cells could still be detected in the epiblast
and in all epiblast derivatives, including the extraembryonic
Figure 1. HBE is an enhancer active in pluripotent cells. (A) HBE is a hotspot for the binding of pluripotency factors and Smad3. Nodal
regulatory elements are represented by green boxes and Nodal exons by blue boxes. Binding peaks of Nanog, Sox2, Klf4, Oct4, and Smad3 at the
Nodal locus in ESCs are represented by black bars that represent either the summit of the peak of ChIP-seq data or its center for ChIP-chip data
aligned to UCSC Genome Browser on Mouse Feb. 2006 (NCBI36/mm8) Assembly (http://genome.ucsc.edu/). (B and C) Luciferase reporter assays for
early Nodal enhancers using either a minimal (E1b) or the endogenous promoter (NIS), in ESCs (B), or in EpiSCs (C). Luciferase activities are shown
relative to HBE construct. An asterisk indicates significant differences from the control (ctrl) (p,0.01).
doi:10.1371/journal.pbio.1001890.g001
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mesoderm (Figure 2G–G0 and unpublished data). However, they
constituted a steadily declining fraction of these tissues. At E8.0,
fluorescent nuclei were still detected in the node and in cells
scattered in all three germ layers along the full length of the
headfold stage embryo (Figure 2H,I). By E8.5, HBE-YFP
expression was no longer detected (unpublished data).
Although HBE-YFP fluorescence just became detectable at
E3.5, in situ hybridization with a YFP probe detected expression
of the transgene in the ICM of all E3.5 transgenic embryos
analyzed (n=16/16; Figure 2J), whereas a similar analysis
previously detected the ASE-YFP transgene in the ICM of no
more than 50% of the embryos [6] (A.P.G. and J.C., unpublished
data).
The expression profile of HBE-YFP does account for the early
aspects of Nodal expression that were not fully recapitulated by the
ASE transgene. It suggests HBE could be involved in the
regulation of Nodal expression from its onset at E3.5 until late
gastrulation stages.
HBE Enhancer Activity Is Critically Dependent on a Single
Oct4 Binding Site
The fact that HBE is a hotspot for the binding of pluripotency
factors in ESCs suggests that this sequence is the interface enabling
these factors to modulate Nodal expression. To test this hypothesis
we first assessed the influence of Oct4 and Nanog on HBE
enhancer activity, using genetically modified ESC lines. RCNbH
Figure 2. HBE-YFP expression is detected between E3.5 and E8.0. (A–A0, B–B0, F–F0, G–G0) Detection of Oct4 and HBE-YFP in E3.5 (A–A9), E4.5
(B–B9), E5.5 (F–F9), or E6.5 (G–G9) HBE-YFP transgenic mouse embryos. (C–C0) Detection of Nanog (C) and HBE-YFP (C9) in an E4.5 HBE-YFP transgenic
mouse embryo (C0). (D–E0) Detection of Gata4 (D and E) and HBE-YFP (D9 and E9) in E3.75 (D0) or E4.5 (E0) embryos. Arrowheads indicate co-expressing
nuclei. (H–I) Expression of HBE-YFP in the epiblast (H) and the node (I) of an E7.5 embryo. Images A to I are single confocal sections. Cortical actin in
blue. n is the number of representative embryos on the total number of HBE-YFP embryos analyzed. (J) In situ hybridization for YFP in an E3.5 HBE-
YFP embryo. n is the number of stained embryos on the total number of HBE-YFP embryos analyzed. Scale bar, 25 mm (except in G, H, I, and J where
scale bar, 50 mm).
doi:10.1371/journal.pbio.1001890.g002
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ESCs contain a conditional allele of Nanog, which can be deleted
by exposure to Tamoxifen—triggering GFP expression [37].
Luciferase assays showed that the enhancer activity of HBE was
not affected by the resulting absence of Nanog (Figure 3A),
indicating that it is not via HBE that Nanog represses Nodal
expression [19]. Successful deletion of Nanog was confirmed by the
up-regulation of GFP and the downregulation of Nanog itself
(Figure S2A–B0), whereas Oct4 expression was maintained (Figure
S2C–D0). In contrast, in ZHBTc4 ESCs, where Doxycyclin
treatment induces a knockdown of Oct4 [38], Oct4 depletion
drastically down-regulated the expression of HBE constructs
(Figure 3B), suggesting that HBE mediates the influence of Oct4
on Nodal expression [19]. Successful down-regulation of Oct4 was
confirmed by immunofluorescence (Figure S2E–F9). However,
these experiments could not establish whether the activity of HBE
required a direct interaction between this enhancer and Oct4.
A systematic analysis was then undertaken to determine how the
major pluripotency factors known to bind HBE contribute to its
transcriptional activity in ESCs. Sequence comparison among
eutherian mammals had uncovered four conserved regions within
HBE, which we called HBE1 to 4 (Figure 3C). We used the BiFa
bioinformatic tool [6,39] to identify putative binding sites for
Oct4, Nanog, Sox2, and Klf4 over the entire HBE sequences
(Figure 3C and Figure S3A). Putative binding sites for Nanog/
Sox2 (2), Sox2 (1), Klf4 (10), and Oct4 (3) were found in HBE2
and 3. Only these two regions showed significant enhancer
activity, which was drastically increased when these two sequences
were combined (Figure 3D). Fragments of HBE23 of increasing
Figure 3. HBE enhancer activity depends on Oct4. (A, B, D–F) Luciferase reporter assays in ESCs using either a minimal (E1b) promoter or the
endogenous sequence (NIS). (A) HBE activity before and after Nanog deletion in RCNbH cells. (B) HBE activity before and after Oct4 inactivation in
ZHBTc4 cells. An asterisk denotes significant differences between Oct4+ and Oct4 – (p,0.01). (C) Positions of putative binding sites for Nanog, Sox2,
Klf4, and Oct4 on HBE subregions 1 to 4 (Figure S3A). An asterisk indicates the main Oct4 binding site detailed in (G). (D) Transcriptional activity of
HBE subregions. An asterisk indicates significant differences from control (ctrl) (p,0.01). (E) Transcriptional activity of HBE 2–3 serial deletions. (F)
Effect of mutations on transcriptional activity of HBE 2–3. NS*, all Nanog and Sox2 sites are mutated; K*, all Klf4 sites are mutated; O*, main Oct4 site is
mutated; NSKO*, all sites identified in (C) are mutated. An asterisk denotes significant differences from HBE 2–3 (p,0.01). (G) Conservation of the
main Oct4 binding site in eutherian mammals. Canonical Oct4 binding site is underlined, and extended Oct4 binding is shaded in yellow. (H–I0)
Electroporation of a WT (H) or a mutant (I) HBE-YFP construct in mouse blastocysts. mCherry was coelectroporated as a positive control. n is the
number of YFP-positive (H) or negative (I) embryos on the total number of mCherry-positive embryos analyzed. Single confocal sections. Cortical
actin in blue. Scale bar, 25 mm.
doi:10.1371/journal.pbio.1001890.g003
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lengths were then assayed to identify subregions that are critical for
this activity. Significant increases in enhancer activity were seen
when fragments HBE2d, which contains a cluster of putative Klf4
binding sites, and HBE3d, which contains putative Oct4 and
Nanog/Sox2 binding sites, were added to the reporter construct
(Figure 3E). The addition of HBE3d resulted in the most dramatic
gain in enhancer activity.
To assess the relevance of these binding sites to HBE enhancer
activity, they were all mutated in HBE23-E1b and HBE-NIS
luciferase constructs. Point mutations were designed with the help
of the BiFa algorithm so as to prevent binding of the relevant
transcription factor to its putative target sequence, while
minimizing effects on the binding of other transcription factors.
The impact of each mutation on transcription was first assessed
separately and then in combination with others. We found that
putative binding sites for all four factors—Nanog, Sox2, Oct4, and
Klf4—were contributing to HBE23 enhancer activity in ESCs
(Figure 3F). Mutations in Klf4 and Oct4 binding sites were,
however, far more detrimental to this activity than mutations in
Nanog and Sox2 binding sites. In particular, the elimination of the
first Oct4 binding site in HBE3d was the single mutation causing
the most dramatic drop in luciferase activity (Figure 3F). Its
combination with mutations in the two other putative Oct4
binding sites did not reduce this activity further (Figure S3B). We
confirmed that this single mutation was able to prevent the binding
of Oct4 in gel shift assays with ESC extracts (Figure S4A).
Mutations in Nanog and Sox2 putative binding sites only had a
significant impact on Luciferase activity when they were all
combined in an NIS-driven construct, and still the decrease was
modest (Figure 3F). The BiFa algorithm identified all putative
Nanog binding sites in HBE as putative, lower ranking, Sox2
binding sites. In gel shift assays, extract from Nanog-depleted
RCNbH ESCs slowed the migration of the target sequence we
tested, indicating that it was bound by one other factor at least
(Figure S4B). The mutated version of the sequence, however,
prevented this binding, indicating that although some factor, such
as Sox2, could possibly compensate for the absence of Nanog in
RCNbH ESCs, our mutation allowed the contribution of their
common binding sites to HBE and Nodal regulation to be assessed.
Together with the Oct4 result, this suggested that our approach to
mutation design was effective. We found that the addition of all
Nanog and Sox2 mutated binding sites to a construct already
containing all Klf4 and Oct4 mutated binding sites did not reduce
its transcriptional activity further (NSKO*; Figure 3F), suggesting
that the contribution of Nanog and Sox2 to HBE enhancer activity
is secondary to that of Oct4 and Klf4.
Notably, we found that the first Oct4 binding site in HBE3d, the
one most critical to HBE enhancer activity, is the most conserved
of all the putative binding sites we identified in HBE, as it is the
only one present in all mammalian genomes tested so far
(Figure 3G). Furthermore, this conserved stretch of DNA contains
an extended version of the Oct4 binding site that recent evidence
suggests can be bound by Oct4 alone and is critical to its
reprogramming function [40,41].
To confirm the relevance of our findings to the regulation of
HBE in vivo, we electroporated eight-cell stage embryos with
constructs in which a nuclear version of Venus-YFP is under the
control of either native HBE or its KO* version, where all Klf4
and Oct4 putative binding sites are mutated. Electroporation
efficiency was assessed by co-electroporating a construct express-
ing mCherry under the control of the strong promoter CAG.
Electroporated embryos were cultured 30 h, allowing most of
them to reach the blastocyst stage. A majority of the embryos that
had been electroporated with the native HBE construct (n=19/
24) showed YFP expression in a few cells. In contrast, embryos
that had been electroporated with the mutated HBE-KO*
construct showed only very weak or undetectable expression of
YFP (12/12; Figure 3H–I0).
These results indicate that both in ESCs and in preimplantation
embryos, HBE is under the control of pluripotency transcription
factors, notably Oct4 and Klf4, whose cognate binding sites are
critical to its enhancer activity.
The Enhancer Activity of HBE Is Also Dependent on
Activin/Nodal Signaling
The fact that not all E3.5 to E4.5 Oct4-positive ICM cells
expressed HBE-YFP in transgenic embryos suggested that some
other factor was essential for the activation of HBE. Several studies
have shown that Nodal expression in ESCs is dependent on
Activin/Nodal signaling [16–18]. Furthermore, a recent genome-
wide ChIP study showed that, in ESCs, pSmad3 co-occupies the
genome with Oct4, with which it forms a complex, and that this
correlated with sensitivity to TGFb signaling for Oct4-bound
genes [42]. Notably, this study showed that with respect to Nodal
expression, Oct-4 depletion led to a 5-fold reduction in its response
to Activin exposure. Two of the positions where both Oct4 and
Smad3 were found to bind are within HBE (Figure 1A). Our own
results showed that reporter constructs and reporter transgenes for
the Activin/Nodal signaling-dependent ASE had very limited
transcriptional activity in ESCs (this study, and N. Sasaki, A.B.,
and J.C., unpublished results). Together, these data strongly
suggested that Activin/Nodal signaling might be the other signal
required to elicit HBE activation in preimplantation epiblast. To
test this hypothesis, we cultured E2.5 HBE-YFP embryos for 48 h
in the presence of 40 mM SB-431542, a pharmacological inhibitor
of the type I Activin receptors ALK4, 5, and 7 [43]. We found that
SB-431542–treated embryos had a similar number of Oct4-
positive cells as DMSO-treated control embryos, indicating that at
this concentration the formation of the ICM is not significantly
affected (Figure 4A–E). SB-431542 exposure nevertheless resulted
in a drastic reduction of the percentage of YFP-positive embryos
and of YFP-positive cells among Oct4-positive ones. In addition,
cells that expressed the transgene in SB-431542–treated embryos
did so at a lower level than their counterparts in DMSO-treated
embryos (unpublished data). We conclude that HBE-YFP
expression is dependent on Activin/Nodal signaling, presumably
reflecting a similar requirement for the activation of the
endogenous HBE.
HBE Conditions ASE Activation in Differentiating ESCs
Having established that HBE is an enhancer active in ESCs and
in the mouse embryo, we assessed its contribution to Nodal
expression. We generated a targeting construct in which HBE was
floxed and the first 80 bp of Nodal ORF were replaced by the
coding sequence for a destabilized nuclear Venus-YFP, so that the
expression of the modified allele could be monitored (Figure S5A
and Figure 5A). Successful targeting of the Nodal locus in ESCs was
confirmed by PCR and Southern hybridization (Figure S5B–D).
Almost all recombinant cells expressed the YFP, although at
different levels (Figure 5B–B0). In contrast, Cre-mediated deletion
of HBE resulted in most cells having completely lost YFP
expression 2 d after transfection, indicating that HBE is essential
to Nodal expression in ESCs (Figure 5C–C0). The few cells
expressing YFP (,7% of total) tended to be found at the periphery
of colonies and to have low or no Oct4 expression, suggesting they
corresponded to differentiating cells in which Nodal expression was
driven by other enhancers.
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To investigate this possibility, we analyzed the expression of the
HBE-deleted allele in EpiSCs, where our luciferase-based assays
had shown that ASE is the predominant Nodal enhancer. We thus
induced ESCs carrying the conditional HBE allele NodalcondHBE-YFP
to differentiate into EpiSCs. Real-time PCR (RT-PCR) analysis of
the expression dynamics of four key markers—Klf4, Oct4, FgF5,
and Bra—confirmed the successful conversion of the cells to an
EpiSC identity (Figure S6A). RT-PCR analysis showed that the
NodalcondHBE-YFP allele and the wild-type (WT) Nodal allele followed
similar expression dynamics, indicating that the conditional allele
is a fair reporter of WT Nodal expression (Figure S6B and
unpublished data). EpiScs carrying the NodalcondHBE-YFP allele were
then transfected with two constructs expressing either the Cre
recombinase or the fluorescent marker mCherry. Widespread
mCherry expression confirmed that transfection was efficient
(Figure S6C–C9), whereas RT-PCR on genomic DNA showed
that HBE deletion frequency was close to 90% 4 d after
transfection (Figure S6D). We found that 6 d after transfection
the expression of NodalDHBE-YFP was maintained at a level similar to
that of the undeleted allele (Figure 5D–E0, Figure S6E). This result
indicates that HBE is not required for the expression of Nodal in
EpiSCs, which is thus driven by another Nodal enhancer,
presumably ASE.
To investigate the dynamics of the transition from an HBE-
driven Nodal expression to an ASE-driven one, we induced ESCs
carrying either the conditional HBE allele NodalcondHBE-YFP or the
HBE-deleted allele NodalDHBE-YFP to differentiate into EpiSCs.
RT-PCR analysis showed, as expected, that the expression of
NodalDHBE-YFP was much lower than that of NodalcondHBE-YFP at the
beginning (Figure 6A). Surprisingly, it did not recover, even after
10 d of differentiation. Comparison with the expression of the
undeleted allele showed an average difference of about 80%, and
immunofluorescence detected the YFP in just a few cells
(Figure 6B–D0). Like in ESC colonies, these rare YFP-positive
cells had lower or no Oct4 expression (Figure 6D0). Together with
the earlier finding that HBE is not required for NodalDHBE-YFP
expression in EpiSCs, this indicates that prior to its deletion in
EpiSCs, HBE contributed to a modification of the locus critical for
the activation of ASE, which allowed NodalDHBE-YFP to be
expressed in EpiSCs. These results demonstrate that during the
conversion of ESCs into EpiSCs, HBE is initially required to
promote the activation of ASE.
As ASE is dependent on Activin/Nodal signaling and as Nodal
in NodalDHBE-YFP cells is still produced by the WT allele, we
hypothesised that HBE is required to potentiate the activation of
ASE at the chromatin level. We used ChIP to track changes in the
distribution of the mutually exclusive H3K27me3 and H3K27ac
histone marks at different positions in the locus. This analysis
revealed that after HBE deletion, a region 59 to the ASE sees a 2.5-
fold increase of the repressive H3K27me3 mark and a 2-fold
decrease of the active H3K27ac mark. These modifications are
specific to the recombinant allele. No changes were detected at the
39 end of the autoregulatory enhancer. No changes either were
detected immediately upstream and downstream of the deleted
HBE (Figure 6E–G). This result demonstrates that HBE controls
the chromatin status of a region adjacent to ASE and therefore
suggests that it is via the recruitement of chromatin modifiers that
HBE exerts an influence over ASE activation.
HBE Is Required for Nodal Expression in the Mouse
Embryo
To investigate whether HBE is necessary for the expression of
Nodal in vivo as it is in vitro, chimeric embryos were generated.
NodalcondHBE-YFP and NodalDHBE-YFP cells were first stably transfected
with mCherry so that they could be traced in chimeric embryos.
Small groups of these cells were then aggregated with E2.5
morulae, and the resulting blastocysts were either cultured in vitro
until the equivalent of stage E4.5 or reimplanted into pseudo-
pregnant mice and allowed to develop in utero until the equivalent
of stage E6.5. Chimerism was very high as judged by the number
of mCherry-positive cells in the epiblast of the aggregation
chimeras. Embryos generated from NodalcondHBE-YFP cells expressed
YFP in the epiblast (n=34/48 of stage E4.5 and 7/7 of stage E6.5
embryos analyzed; Figure 7A and C), and this expression was
consistent with the expected expression profile for Nodal, notably
showing a restriction to the proximal posterior epiblast at E6.5. In
contrast, embryos generated from NodalDHBE-YFP cells did not
express the fluorescent marker or expressed it at very low levels in
just a few cells (n=44/45 of stage E4.5 and 7/7 of stage E6.5
embryos analyzed; Figure 7B and D), indicating that HBE is
required for the activation of Nodal transcription in epiblast cells in
vivo, as in vitro differentiation experiments suggested.
Discussion
HBE Is an MTL at the Nodal Locus
Genome-wide ChIP studies have shown that in ESCs,
pluripotency factors co-occupy the genome at specific multi-
transcription factor-binding loci (MTL) through which they
control the pluripotent state of the cells [22,24–26,44]. These
studies led to the view that the core transcription factors of the
Figure 4. HBE-YFP expression in the blastocyst is dependent
on Activin/Nodal signaling. (A–B) Detection of Oct4 (A, B) and HBE-
YFP (A9, B9) in transgenic mouse blastocysts cultured either in DMSO (A–
A0) or SB431542 (B–B0). Scale bar, 25 mm. Single confocal sections.
Cortical actin in blue. (C) Percentage of YFP-positive embryos after 24 h
culture in DMSO or in SB431542. (D) Percentage of YFP positive ICM
nuclei in embryos after 24 h culture in DMSO or SB431542. An asterisk
indicates significant difference from the control (ctrl) (p,0.01). (E)
Number of Oct4-positive ICM cells per embryo after 24 h culture in
DMSO or in SB431542.
doi:10.1371/journal.pbio.1001890.g004
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pluripotency gene regulatory network (GRN), Oct4, Nanog, and
Sox2, form an interconnected autoregulatory loop that positively
regulates their own promoters, activate the expression of genes
necessary to maintain the pluripotent state, and contribute to the
repression of genes promoting differentiation [45–47]. We
identified HBE as an MTL at the Nodal locus. Our results confirm
that this region is a target of the molecular machinery of
pluripotency and of the Activin/Nodal signaling pathway, as
ChIP studies predicted [22,24–26,42].
HBE Enhancer Activity Depends on Pluripotency Factors
and Activin/Nodal Signaling
We found that HBE has enhancer activity in ESCs, as was the
case for all Oct4/Sox2/Nanog MTLs tested so far [22,47]. HBE is
in fact the only Nodal enhancer active in ESCs. Moreover, it is
activated early on during mouse embryonic development.
Transgenic embryos expressing YFP under the control of HBE
up-regulate the fluorescent marker in the ICM of the E3.5
blastocyst. Its expression is then restricted to the embryonic
epiblast and is maintained in its embryonic and extra-embryonic
derivatives until organogenesis starts at E8.5, at which point Oct4
expression and pluripotency are lost [48].
We showed that the enhancer activity of HBE is dependent on
Oct4 and Klf family members. In fact Oct4 is the master
pluripotency factor most critical to this activity. This is consistent
with studies suggesting that unlike other master pluripotency
factors, Oct4 is a strong transcriptional activator [49]. It appears to
function as a pioneer factor at enhancers, opening up the
chromatin and allowing other factors, such as pSmad3, to access
their binding sites [42]. The main Oct4 binding site in HBE is the
only one of all the putative pluripotency factors binding sites we
identified that is extensively conserved among placental mammals,
suggesting that HBE evolved around this particular sequence.
We also found that the enhancer activity of HBE is dependent on
Activin/Nodal signaling and we showed previously that Activin/
Nodal signaling is activated in Nodal2/2 blastocysts [6]. In other
animal models, there is consistent evidence of another TGFb family
member acting upstream of early Nodal expression [50–54]. Gdf1
and Gdf3, two possible TGFb-related candidates in the mouse,
appear however unable to activate the Smad2/3 pathway at
physiological concentrations [55–57]. This was confirmed when we
showed that Gdf3 cannot replace Nodal in vivo [6]. Better candidate
ligands for the early activation of the Smad2/3 pathway and of
HBE are thus Activins, which are present in the ICM as well as in
the oviduct and uterine epithelia prior to implantation [58]. Because
Nodal was also found to be expressed in the endometrium of E3.5
pregnant females, one cannot discount the possibility that Nodal of
maternal origin might be involved in the induction of Nodal
expression in the embryo [59].
Nodal Expression Undergoes a Regulatory Shift During
Epiblast Maturation
The finding that the onset of Nodal expression is dependent on
the pluripotency GRN coincides with a growing realization that in
the context of the embryo so-called pluripotency factors are in fact
actively engaged in promoting development. Nanog, described as
Figure 5. HBE is required for Nodal expression in ESCs but not in EpiSCs. (A) Depiction of the two Nodal alleles (WT on top and recombinant
at the bottom) before and after Cre recombination. (B–C0) Expression of Oct4 (B, C) and YFP (B9, C9) in recombinant ESCs before (B–B0) and after (C–C0)
Cre recombination. (D–E0) Expression of Oct4 (D, E) and YFP (D9, E9) in recombinant EpiSCs, 6 d after transfection with a control plasmid (D–D0) or
with Cre recombinase (E–E0). Single confocal sections. n is the number of YFP-positive colonies. Scale bar, 25 mm.
doi:10.1371/journal.pbio.1001890.g005
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the guardian of pluripotency in ESCs [37], is required in epiblast
precursors to promote, by a non-cell-autonomous mechanism, the
differentiation of adjacent PrE precursors [60]. It has also been
shown recently that Oct4 promotes PrE development through
both cell-autonomous and non-cell-autonomous mechanisms, and
more generally favors embryo development via its control of
multiple metabolic pathways [61]. Recent work indicates that
Activin/Nodal signaling may first be required in the PrE around
E4.0 to specify a subset of Lefty1-expressing PrE cells, the
descendants of which will later give rise to the distal visceral
endoderm (DVE), a group of cells playing a critical role during the
establishment of AP polarity [2,7]. It is therefore possible that the
HBE-dependent expression of Nodal in the blastocyst contributes to
this initial regionalization of the PrE. During the transition from
pre-implantation to postimplantation epiblast, Nodal undergoes a
regulatory shift, from an HBE-driven phase to an ASE-driven one,
which correlates with an increase in its expression levels and an
up-regulation of differentiation promoting downstream targets,
also seen in EpiSCs [6,13,14]. In ESCs, most genes involved in
lineage specification are in a poised state that is transcriptionaly
silent but ready to be activated by developmental signals. This
state is defined by the presence of both active and repressive
histone marks on the promoters of these genes. Repressive marks
are introduced by chromatin modifiers locally recruited by Oct4,
Sox2, and Nanog [47]. Smad2/3 complexes, activated by the
Activin/Nodal pathway, can remove these repressive marks and
induce the expression of downstream targets such as Gsc and
Mixl1. Yet although Nodal is expressed in ESCs, Gsc and Mixl1
remain poised in these cells. This can be partly explained by the
relatively low level of Nodal expression in ESCs and by the co-
expression of genes known to restrain its signaling activity, such as
Smad7, Lefty1, and Lefty2. These data suggest that in the blastocyst
components of the Activin/Nodal signaling pathway are tightly
regulated to ensure proper embryonic and extra-embryonic
development. Initially, activation of Nodal by HBE produces low
levels of the signal that specify certain extra-embryonic precusors,
possibly of the DVE, while minimizing the exposure and the
response of nascent epiblast to prevent its premature differentia-
tion. During subsequent stages of development the autoregulatory
ASE takes over. This shift from an HBE-driven phase to an ASE-
driven one results in an amplification of the Nodal signal, which
triggers the differentiation of the epiblast.
We found that HBE is required in differentiating ESCs for the
activation of ASE. When HBE is deleted in EpiSCs, ASE, the
predominant Nodal enhancer in this cell type, is active. However, if
HBE deletion occurs in ESCs, before their differentiation into
EpiSCs, ASE does not drive expression of the gene. Our results
suggest that once bound to HBE, master pluripotency factors
induce local modifications of the chromatin that in turn affect the
ability of the ASE to interact with the adjacent promoter, and thus
Nodal expression levels. Changes in the combination of HBE-
bound factors, such as those taking place during epiblast
maturation or ESC to EpiSC transition, could modify the effect
HBE has on ASE.
Figure 6. HBE is required to activate ASE during ESC to EpiSC differentiation. (A) RT-qPCR analysis of YFP expression during 10 d of ESC to
EpiSC differentiation of NodalcondHBE-YFP(HBE+) and NodalDHBE-YFP(HBE2) ESCs. One representative experiment. (B) Percentage of difference of YFP
mRNA levels between NodalDHBE-YFP and NodalcondHBE-YFP cells during 10 d of ESC to EpiSC differentiation. Error bars represent the mean + SD of
triplicates and two independent experiments. (C–D0) Expression of Oct4 (C, D) and Venus-YFP (C9, D9) in NodalcondHBE-YFP (C–C0) and NodalDHBE-YFP (D–
D0) ESCs after 10 d of differentiation into EpiSC single confocal sections. n is the number of YFP-positive (C) or YFP-negative (D) samples on the total
number of analyzed samples. Scale bar, 25 mm. (E) Part of the Nodal locus in the WT and the recombinant alleles comprising HBE, the first Nodal exon,
and ASE and showing the position of regions 1–5 amplified in the ChIP experiments shown in (F) and (G). (F–G) ChIP with anti-H3K27me3 (F), anti-
H3K27ac (G), or anti-GFP (F–G) antibodies on material from NodalcondHBE-YFP ESCs (green bars) and NodalDHBE-YFP ESCs (red bars). The position in the
locus of amplified regions 1–5 is shown in (E). An asterisk denotes significant differences between NodalcondHBE-YFP and NodalDHBE-YFP ESCs (p,0.01).
doi:10.1371/journal.pbio.1001890.g006
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Nanog and Oct4 Are Possible Players in the HBE to ASE
Transition
Although Nodal is expressed in ESCs, the autoregulatory
enhancer ASE is not active in these cells. One hypothesis is that
Nanog acts at the Nodal locus to prevent ASE activation. We found
previously that the expression of the ASE-YFP reporter transgene
is only detected in epiblast cells with low or no Nanog [6]. This is
consistent with the results of luciferase assays in ESCs and EpiSCs
that correlate a higher level of ASE transcriptional activity with a
lower level of Nanog. Nanog depletion in ESCs results in an
increase in Nodal expression [19], yet we found that Nanog
depletion, or the elimination of Nanog binding sites, had no effect
on the transcriptional activity of HBE. Because Nanog binds only
HBE at the Nodal locus in ESCs, it must act from this position to
prevent ASE activation. This would keep Nodal expression, and
thus Activin/Nodal signaling, low as long as Nanog is present. Its
down-regulation during the conversion of ESCs into EpiSCs
signaling by unlocking ASE would then allow an increase in
Activin/Nodal.
The dependency of ASE activity on HBE may also involve
Oct4, but in a role opposite to that proposed for Nanog. HBE-
bound Oct4 could promote ASE activation. The mechanism
described for the activation of poised genes by companion
Trim33-Smad2/3 and Smad4-Smad2/3 complexes [62] suggests
a similar scenario for the HBE-dependent activation of ASE. The
Oct4-Smad3 complex bound on HBE could initiate chromatin
modifications that would then allow the interaction of ASE with
the adjacent promoter, leading to the transcriptional activation of
Nodal by the autoregulatory element and the amplification of the
Nodal signal. The results obtained in aggregation chimeras suggest
that ASE may not be the only Nodal enhancer whose activation is
controlled by HBE. The lack of expression of the NodalDHBE-YFP
allele in proximal and posterior epiblast cells at E6.5, where Nodal
expression was shown to be independent of ASE, but where
transgenic PEE reporters were found to be expressed [6,20,63], do
suggest a similar influence on PEE.
The implication of Oct4 in such an unlocking mechanism
would be consistent with recent studies showing that the capacity
of ESCs to differentiate is critically dependent on the level of Oct4
not being too low [64,65]. Such a mechanism may concern the
regulation of differentiation-promoting genes other than Nodal.
Further studies will be necessary to test these hypotheses and get a
better understanding of how HBE-bound factors contribute to the
regulation of Nodal expression.
To conclude, our results complete the picture on the regulation
of Nodal at early stages. They show that HBE has a dual role,
acting both as an enhancer and as a modulator of the activity of
other regulatory elements. Our analysis of its regulation and mode
of action furthers our understanding of the distinct roles assumed
by master pluripotency factors and of the complex fashion in
which the molecular machinery of pluripotency controls gene
expression (Figure 8). It is likely that similar mechanisms are
involved in the regulation of genes other than Nodal. Our results
are consistent with the notion that the need to control Activin/
Nodal signaling is one of the leading influences on the evolution of
the pluripotency GRN.
Materials and Methods
Ethics Statement
Experiments were performed in accordance with French
Agricultural Ministry and European guidelines for the care and
use of laboratory animals. The project has been reviewed and
approved by the Animal Experimentation Ethical Committee
Buffon (CEEA-40). It is recorded under the following reference:
CEB-35-2012.
Figure 7. HBE is required for activation of Nodal in the early mouse embryo. Detection of mCherry (A, B, C, and D) and YFP (A9, B9, C9, and
D9) in E4.5 (A–B0) or E6.5 (C–D0) aggregation chimeras generated from NodalcondHBE-YFP (A–A0 and C–C0) or NodalDHBE-YFP (B–B0 and D–D0) ES cells and
WT embryos. Images are single confocal sections. Cortical actin in blue. n is the number of representative embryos on the total number of embryos
analyzed. Scale bar, 25 mm for E4.5 embryos and 50 mm for E6.5 embryos.
doi:10.1371/journal.pbio.1001890.g007
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Bio-Informatics Analysis
Potential binding sites at endogenous andmutated sequences were
scored statistically using the Binding Factor (BiFa) tool [6]. Weight
matrices from the TRANSFAC database v2009.4 [66] were used.
The alignment of the main Oct4 binding site was retrieved from the
Ensembl database release 73. It belongs to «36 eutherian mammals
EPO LOW COVERAGE» (positions 61,416,797 to 61,416,833 on
mouse chromosome 10). The alignment was visualized using Jalview
2.8 [67] using data for a subset of available species.
ES Cell Culture and Transfection
See Materials and Methods S1 for detailed CCE, ZHbTc4, and
RCNbH mouse ES cell culture conditions. Inhibition of Oct4
expression in ZHbTc4 cells was induced with 0.1 mg/ml
Doxycyclin (Sigma), whereas Nanog knock-down in RCNbH cells
was induced with 1 mM 4-Hydroxy-Tamoxifen (Sigma). We
transiently transfected 200,000 ES cells with 1 mg of any of Firefly
Luciferase constructs and 0.05 mg of the pCAG-Renilla Luciferase
construct (in 50 ml DMEM) and 2 ml Lipofectamine 2000
(Invitrogen—in 50 ml DMEM) according to the manufacturer’s
instructions and harvested them 24 h after transfection.
ESC to EpiSC Differentiation
ES cells were grown as previously described [13]. EpiSC-like
colonies start to appear at passage 3 (day 6), and colonies were
passaged by mechanical dissociation after 30 s treatment with
accutase at room temperature. Colonies were passaged every 2 d
and diluted 3 to 4 times.
Site-Directed Mutagenesis
Site-directed mutagenesis of HBE was performed by two rounds
of PCR amplification. First, complementary primers containing
the point mutations as well as primers complementary to the 59 or
the 39 ends of the sequence were used to amplify the two parts of
HBE that contain the mutated sequence at one end. Then, the two
parts were used as the template for the amplification of the whole
sequence, using the end primers alone. Multiple point mutations
were introduced sequentially. See Materials and Methods S1 for
primer sequences.
Luciferase Assay
The luciferase activities of the cell lysates were measured by
means of the Dual-Luciferase Reporter Assay System (Promega) in
a Berthold Centro LB 960 device. The activity of the firefly
luciferase was measured for 60 s, whereas the activity of the
Renilla luciferase was measured for 0.5 s. Finally, the normalised
values for HBE and HBE23 were arbitrarily set to 10. Activities
are reported as mean standard errors of a minimum of three
independent experiments.
RT-PCR
Total RNA was prepared using NucleoSpin RNA Kit (MN)
followed by DNaseI (Roche) treatment. First-strand cDNA was
synthesised using Vilo reverse transcriptase (Invitrogen). Real-time
PCR was performed using FastStart SYBR Green Master (Roche).
Gene expression was determined relative to Gapdh using standard
curve calibration. All quantitative PCR reactions were performed
in LightCycler 480 (Roche). See Materials and Methods S1 for
primer sequences.
Reporter Constructs and Transgenesis
A DNA construct expressing Venus-YFP fused to 3 NLS was
linearised, gel-purified, and resuspended in Tris 10 mM, EDTA
0.25 mM, pH 7.5. Transgenic founders were obtained after
Figure 8. Model for regulatory shift from HBE to ASE during epiblast maturation. (A) In the late preimplantation epiblast and in ES cells,
pluripotency factors (mainly Oct4) and Nodal/Activin signaling activate HBE, which up-regulates Nodal. However, Nanog bound on HBE represses ASE
so that expression levels of Nodal remain low. (B) In the postimplantation epiblast and in EpiSCs, changes in the combination of HBE-bound factors
allow ASE to take over from HBE as the predominant enhancer driving Nodal expression, and the positive regulatory loop between Nodal and ASE is
established, leading to higher expression levels.
doi:10.1371/journal.pbio.1001890.g008
Control of Nodal Enhancers’ Sequential Activation
PLOS Biology | www.plosbiology.org 11 June 2014 | Volume 12 | Issue 6 | e1001890
microinjection of the DNA into (C57BL/66CBA) F2 fertilized
eggs (1 or 2 ng/ml in injection buffer). Heterozygous embryos
carrying the HBE-Venus transgene were generated by mating
homozygous transgenic males with WT Sw females. The
genotyping was done as described for the ASE-YFP transgene [6].
Embryo Collection, Electroporation, and Culture
Mice mating and embryo collection were as described [6].
Eight-cell stage uncompacted Swiss6Swiss mouse embryos were
collected in M2 (Sigma), shelled in Tyrode’s solution (Sigma), and
electroporated in a flat electrode chamber with a 1 mm gap
between the electrodes (BTX Inc., San Diego, CA) in 16 HBS
DNA solution containing 0.25 mg/ml of the mCherry expressing
control plasmid and 1 mg/ml of the Venus expressing experimental
plasmid. Two sets of four pulses of 1 ms each at 25 V were
delivered, with 100 ms intervals between the pulses and a 1 min
interval between the two sets of inverted polarity. The embryos
were then cultured in G2 (Vitrolife) at 37uC and 5% CO2 for 30 h.
Inhibition of ALK4/5/7 Receptors
Eight-cell stage uncompacted transgenic ASE-YFP embryos
were transferred to an eight-well Netwell plate (Costar) with 400 ml
of G2v5PLUS (Vitrolife). They were cultured for 48 h at 37 uC/
5% CO2 in the presence of 20, 40, or 50 mM SB-431542 (Sigma)
in DMSO, to test for dose toxicity and effectiveness. Control
embryos were cultured in the presence of the same amount of
DMSO. We found as previously that treatment with 40 mM SB-
431542 was required to significantly decrease the activity of the
ASE-YFP transgene [6]. This dose was not toxic for cultured
embryos and was thus chosen to perform similar inhibition
experiments on eight-cell stage uncompacted transgenic HBE-YFP
embryos.
Immunofluorescence
Cells on coverslips were fixed in 4% paraformaldehyde,
permeabilized in PBS/0.3% Triton blocked with 10% FBS in
PBS, and incubated with the primary and secondary antibodies
(diluted in blocking solution). Nuclei were marked with DAPI-
D9564 (Sigma) and cortical actin was marked with 0.5 mg/ml
Alexa 647-conjugated Phalloidin (both Molecular probes) and the
coverslips mounted on slides with Mowiol 4–88 (Sigma). Immu-
nofluorescence on embryo were done as described [6]. See
Materials and Methods S1 for antibody combinations.
In Situ Hybridization
ISH was performed as described previously [6].
Homologous Recombination
166106 CK35 ES cells were transfected with 20 mg of linearised
homologous recombination construct containing 12 Kb of the
Nodal locus with Venus-YFP fused to three NLS and a PEST
sequence replacing the first exon of the gene, two loxP sequences
flanking the HBE, a Neo cassette flanked by two FRTs, and a dtA
cassette. Transfection was performed by electroporation in two
batches of 0.5 ml each in an 0.4 mm gap Biorad cuvette using the
Biorad GenePulser and its Capacitance Extender at 200 V and
950 mF capacitance. Selection was performed with 0.2 mg/ml
G418. Recombinant clones were further tested by PCR and
Southern hybridization.
Chromatin Immunoprecipitation (ChIP)
ChIP experiments were performed as described [68]. All ChIPs
were done in triplicate and analyzed by duplicate qPCRs.
Real-time PCR was performed on Roche Lightcycler using Roche
SYBR Green mix (Roche, Switzerland). Five genomic regions
were chosen on the Nodal locus as shown on Figure 6F. The
occupancy of these regions was quantified by quantitative PCR
analysis of the ratio of the ChIP signal versus the input signal. The
following antibodies were used: anti-acetyl K27-Histone H3
(abcam, ab4729) and anti-trimethyl K2-Histone H3 (Millipore,
07-449), and for mock ChIP, anti-GFP (lifetechnologies, A11122).
See Materials and Methods S1 for primer sequences.
Generation of Aggregation Chimeras
NodalcondHBE-YFP and NodalDHBE-YFP ES cells were labelled with
nuclear mCherry by transfection with a plasmid expressing
mCherry under the control of the strong promoter CAG and
the neomycin resistance gene. mCherry-positive cells were selected
with 0.2 mg/ml G418. Eight-cell stage Swiss 6 Swiss mouse
embryos were collected in M2 (Sigma), shelled in Tyrode’s
solution (Sigma), and co-cultured in G2 (Vitrolife) at 37uC and 5%
CO2 with groups of 10–15 of mCherry labelled, Nodal
condHBE-YFP,
or NodalDHBE-YFP ES cells. Aggregated chimeras were cultured in
G2 for 60–72 h until they reached the equivalent of stage E4.5 or
transferred 36 h later into the uterus (up to 10 blastocysts) of E2.5
pseudopregnant mice, where they developped until they reached
the equivalent of stage E6.5.
Imaging and Image Processing
Acquisitions of fixed embryos were performed at Imago Seine
Core Facility using confocal microscopes (Zeiss LSM 710 and
780). See supplementary experimental procedures for details
(Materials and Methods S1). The total number of cells and/or of
labeled cells was obtained by counting cell nuclei manually. All
images shown in the article are one 5 mm confocal section.
Supporting Information
Figure S1 HBE contains epigenetic signatures characteristic of
active enhancers. ChIP-seq data for H3K4me3, H3K27me3, and
H3K4me1 were subtracks of the Broad H3 ChIP-seq track in the
UCSC genome browser on Mouse Feb. 2006 (NCBI36/mm8)
Assembly and represent ChIP-seq density signal. ChIP-seq data
for p300 and H3K27ac were wig files corresponding to the
reference paper extracted from GEO (Accession GSE24165) and
uploaded in the UCSC genome browser (http://genome.ucsc.
edu/).
(TIF)
Figure S2 Confirmation of Nanog deletion in RCNbH ES cells
and Oct4 inhibition in ZHBTc4 ES cells. (A–B0) RCNbH cells,
stained for GFP (A9 and B9) and Nanog (A0 and B0) before (A–A0)
and after (B–B0) deletion of Nanog by the addition of Tamoxifen.
(C–D0) RCNbH cells, stained for GFP (C9 and D9) and Oct4 (C0
and D0) before (C–C0) and after (D–D0) deletion of Nanog by the
addition of Tamoxifen. (E–F9) ZHBTc4 cells, stained for Oct4
before (E9) and after (F9) inhibition of Oct4 by the addition of
doxycyclin. DAPI stains ESC nuclei. One confocal section. Scale
bar, 25 mm.
(TIF)
Figure S3 Pluripotency factor binding sites in HBE. (A)
Sequence of HBE. Regions 1–4 are separated by ‘‘//’’. Subregions
a–d within regions 2 and 3 are separated by ‘‘/’’. Transcription
factor binding sites of interest are highlighted. The mutated
nucleotides are underlined. Long clusters of transcription factor
binding sites that were deleted are in bold characters. Nanog and
Oct4 binding sites tested in gel shift assays are in black boxes.
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(B) Luciferase reporter assays on ESCs using the minimal
promoter E1b. Luciferase activity before (HBE23) and after
mutation of the main Oct4 binding site (HBE23-O*) or of all three
Oct4 binding sites (HBE23-O*). Luciferase activities are shown
relative to HBE23 construct fixed to 10 arbitrary units. Bars
represent mean 6 SD of a minimum of three independent
experiments performed for each condition. Ctrl, control E1b
vector.
(TIF)
Figure S4 Oct4 specifically binds the identified conserved Oct4
binding site in ESCs. Representative gel-shift assays performed
with ES cell extracts and double-strand 32P oligonucleotide. (A)
ZHBTc4 ES cells (Doxycyclin treated – Z+, in which Oct4 was
depleted – or not – Z–). Oct4 oligonucleotide corresponding to the
main Oct4 binding site, WT, or mutated (MUT) as in the
luciferase assay constructs (Figure S3B). The migration of WT
oligonucleotides were shifted in the presence of Z– cell extract
expressing Oct4 (line 5A), but not in absence of Oct4 (Z+ cells, line
12A). Oct4 specific antibodies destabilized the complexes (line 6A).
This shift was not observed with mutated oligonucleotides (MUT,
line 10A). (B) RCNbH ES cells (tamoxifen treated – R+, in which
Nanog was depleted – or not – R–). Nanog oligonucleotide
corresponding to the identified Nanog binding site in HBE2a,
WT, or mutated (MUT) as in the luciferase assay constructs. The
migration of WT oligonucleotides in the presence of R– cell extract
expressing Nanog (line 2B) or R+ cell extract without any Nanog
(6B) was shifted, but not that of mutated oligonucleotides (lines 9B
and 11B). This shift was not observed with mutated oligonucle-
otides (MUT, line 10A). Arrows, nonspecific DNA–protein
complexes (not abolished by incubation with the cold probe).
Arrowheads, specific DNA–protein complexes. Vertical bar,
typical HSF/HSE complexes, loaded as a positive control of the
assay to assess the quality of ES cell extracts. HSE (Heat Shock
Element) is bound by HSFs, transcription factors highly expressed
in ES cells and in preimplantation embryos [69].
(TIF)
Figure S5 Homologous recombination in ESCs. (A) Represen-
tation of the homologous recombination strategy. Probes,
restriction sites, and the resulting fragments are depicted. (B)
Southern blot showing successful targeting of the 59 end of the
homologous recombination construct. 59 probe used. (C) Southern
blot showing successful targeting of the 39 end of the homologous
recombination construct. 39 probe used. (D) Southern blot
showing conservation in the recombinant allele of the 59 loxP
sequence. loxP probe used. (E) Representation of HBE deletion in
the recombinant allele. (F) Southern blot showing successful HBE
deletion after transfection of the Cre recombinase. Venus probe
used. Each gel was photographed after ethidium bromide staining,
and the image of the ladder lane was associated with that of the
corresponding autoradiogramme.
(TIF)
Figure S6 HBE is dispensable for Nodal expression in EpiSCs.
(A) Representative RT-qPCR for several different markers
confirming the differentiation of ES cells into EpiSCs, in
NodalcondHBE-YFP(HBE+) and NodalDHBE-YFP(HBE–) ES cells during
10 d of differentiation into EpiSCs. (B) Representative RT-qPCR
showing changes in Nodal and YFP expression of NodalcondHBE-
YFP(HBE+) ES cells during 10 d of differentiation into EpiSCs. (C–
C9) mCherry expression confirming the efficient transfection of the
Cre recombinase in NodalcondHBE-YFP EpiSCs cells 6 d after the
transfection. The field is the same as in Figure 5D–E. (D) Genomic
RT-PCR showing efficiency of conditional HBE allele deletion
after transfection with Cre recombinase. (E) RT-PCR showing
levels of YFP in NodalcondHBE-YFP EpiS cells cultured for 6 d after
transfection of Cre recombinase to delete HBE (+Cre).
(TIF)
Materials and Methods S1 Supplementary materials and
methods.
(DOCX)
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